IT202000000616A1 - Impiego di glutaraldeide deprivata di acidi per la preparazione di tessuti biologici per bio-protesi e prevenzione della loro calcificazione - Google Patents

Impiego di glutaraldeide deprivata di acidi per la preparazione di tessuti biologici per bio-protesi e prevenzione della loro calcificazione

Info

Publication number
IT202000000616A1
IT202000000616A1 IT102020000000616A IT202000000616A IT202000000616A1 IT 202000000616 A1 IT202000000616 A1 IT 202000000616A1 IT 102020000000616 A IT102020000000616 A IT 102020000000616A IT 202000000616 A IT202000000616 A IT 202000000616A IT 202000000616 A1 IT202000000616 A1 IT 202000000616A1
Authority
IT
Italy
Prior art keywords
calcification
glutaraldehyde
prosthesis
bio
preventing
Prior art date
Application number
IT102020000000616A
Other languages
English (en)
Inventor
Giovanni Bussolati
Benedetta Bussolati
Michela Gastaldi
Original Assignee
Addax Biosciences S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addax Biosciences S R L filed Critical Addax Biosciences S R L
Priority to IT102020000000616A priority Critical patent/IT202000000616A1/it
Publication of IT202000000616A1 publication Critical patent/IT202000000616A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
IT102020000000616A 2020-01-15 2020-01-15 Impiego di glutaraldeide deprivata di acidi per la preparazione di tessuti biologici per bio-protesi e prevenzione della loro calcificazione IT202000000616A1 (it)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102020000000616A IT202000000616A1 (it) 2020-01-15 2020-01-15 Impiego di glutaraldeide deprivata di acidi per la preparazione di tessuti biologici per bio-protesi e prevenzione della loro calcificazione

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102020000000616A IT202000000616A1 (it) 2020-01-15 2020-01-15 Impiego di glutaraldeide deprivata di acidi per la preparazione di tessuti biologici per bio-protesi e prevenzione della loro calcificazione

Publications (1)

Publication Number Publication Date
IT202000000616A1 true IT202000000616A1 (it) 2021-07-15

Family

ID=70295755

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102020000000616A IT202000000616A1 (it) 2020-01-15 2020-01-15 Impiego di glutaraldeide deprivata di acidi per la preparazione di tessuti biologici per bio-protesi e prevenzione della loro calcificazione

Country Status (1)

Country Link
IT (1) IT202000000616A1 (it)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125813A1 (en) 2002-01-03 2003-07-03 Carpentier Sophie M. Treatment of bioprosthetic tissues to mitigate post implantation calcification
US20060217804A1 (en) * 2005-03-25 2006-09-28 Dove Jeffrey S Treatment of bioprosthetic tissues to mitigate post implantation calcification
EP1861132A2 (en) 2005-03-25 2007-12-05 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US8426199B2 (en) 2007-02-24 2013-04-23 Gfe Nanomedical International Ag Method for the treatment of biological tissue of animal or human origin, such as porcine, bovine pericardium or human cadaver heart valves, and biological tissue treated accordingly
US9095430B2 (en) 2010-08-24 2015-08-04 Southern Lights Ventures (2002) Limited Biomaterials with enhanced properties and devices made therefrom

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125813A1 (en) 2002-01-03 2003-07-03 Carpentier Sophie M. Treatment of bioprosthetic tissues to mitigate post implantation calcification
US20060217804A1 (en) * 2005-03-25 2006-09-28 Dove Jeffrey S Treatment of bioprosthetic tissues to mitigate post implantation calcification
EP1861132A2 (en) 2005-03-25 2007-12-05 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US8426199B2 (en) 2007-02-24 2013-04-23 Gfe Nanomedical International Ag Method for the treatment of biological tissue of animal or human origin, such as porcine, bovine pericardium or human cadaver heart valves, and biological tissue treated accordingly
US9095430B2 (en) 2010-08-24 2015-08-04 Southern Lights Ventures (2002) Limited Biomaterials with enhanced properties and devices made therefrom

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CARPENTIER A, J. THORAC. CARDIOVASCULAR SURGER, vol. 58, 1969, pages 467 - 83
CARPENTIER A.: "biological tissues in heart Valve Replacement", 1972, BUTTERWORTH
GOLOMB G., AM. J PATHOL, vol. 127, 1987, pages 122 - 130
LEE CH ET AL., J. BIOMED. MATER. JOURNAL OF CLINICAL AND CLINICAL RESEARCH, vol. 42, no. 1, 1998, pages 30 - 7
LEE W ET AL., BIOMATERIALS, vol. 21, no. 22, 2000, pages 2323 - 30
LONESCU MI ET AL., ANN THORAC SURG, vol. 34, 1982, pages 265 - 277
MAGLIGAN DJ ET AL., J THORAC CARDIOVASCULAR SURG, vol. 90, 1985, pages 872 - 881
MILAN A ET AL., AM J CARDIOL, vol. 53, 1984, pages 1066 - 1070
MUNNELLY A ET AL., BIOMATERIALS, vol. 33, no. 1, 2012, pages 1 - 8
PARK CS ET AL.: "interact Cardiovascular", THORAC SURG, vol. 25, no. 3, 1 September 2017 (2017-09-01), pages 391 - 399
REUL GJ ET AL., J VASC SURG, vol. 2, 1985, pages 192 - 204
SANDERS SP ET AL., AM J CARDIOL, vol. 46, 1980, pages 429 - 438
SCHOENET FJ ET AL., CARDIOL CLIN, vol. 2, 1984, pages 717 - 739

Similar Documents

Publication Publication Date Title
Wang et al. Fluvastatin inhibits the expression of tumor necrosis factor-+ A7E and activation of nuclear factor-+ A7o-B in human endothelial cells stimulated by C-reactive protein
Gómez-Guzmán et al. Chronic (−)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
Lu et al. Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS
CU20110236A7 (es) Anticuerpos monoclonales completamente humanos contra el inhibidor de la vía del factor tisular (tfpi)
EA201171306A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
BRPI0408814A (pt) composição farmacêutica, e, alimento para o cuidado da saúde
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ECSP12012134A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
UA114304C2 (uk) Спосіб зниження сироваткових рівнів сечової кислоти у людини
Gutiérrez-Venegas et al. Apigenin reduce lipoteichoic acid-induced inflammatory response in rat cardiomyoblast cells
EA200801107A1 (ru) Пиразолы, пригодные для лечения воспалений
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
GB0025670D0 (en) Preparation for the relief of inflammatory disease
WO2010144678A3 (en) Generation of vascularized human heart tissue and uses thereof
Hsu et al. Eicosapentaenoic acid attenuated oxidative stress-induced cardiomyoblast apoptosis by activating adaptive autophagy
FR2934052B1 (fr) Dosage de l'activite du facteur tissulaire circulant
Tatipamula et al. Anti-inflammatory properties of Dirinaria consimilis extracts in albino rats
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
IT202000000616A1 (it) Impiego di glutaraldeide deprivata di acidi per la preparazione di tessuti biologici per bio-protesi e prevenzione della loro calcificazione
WO2004087181A8 (de) WIRKSTOFFKOMBINATION VON ω3-FETTSÄUREHALTIGEN ÖLEN MIT POLYPHENOLHALTIGEN PFLANZENEXTRAKTEN UND DEREN VERWENDUNG
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen